Sodium/bile acid cotransporter

Sodium/bile acid cotransporter also known as the Na+-taurocholate cotransporting polypeptide (NTCP) or liver bile acid transporter (LBAT) is a protein that in humans is encoded by the SLC10A1 (solute carrier family 10 member 1) gene.[5][6]

SLC10A1
Identifiers
AliasesSLC10A1, NTCP, solute carrier family 10 member 1
External IDsOMIM: 182396 MGI: 97379 HomoloGene: 31126 GeneCards: SLC10A1
Gene location (Human)
Chr.Chromosome 14 (human)[1]
Band14q24.1Start69,775,416 bp[1]
End69,797,241 bp[1]
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez

6554

20493

Ensembl

ENSG00000100652

ENSMUSG00000021135

UniProt

Q14973

O08705

RefSeq (mRNA)

NM_003049

NM_001177561
NM_011387
NM_001361972

RefSeq (protein)

NP_003040

NP_001171032
NP_035517
NP_001348901

Location (UCSC)Chr 14: 69.78 – 69.8 MbChr 12: 80.95 – 80.97 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Structure

Sodium/bile acid cotransporters are integral membrane glycoproteins. Human NTCP contains 349 amino acids and has a mass of 56 kDa.[7]

Function

Bile acid:sodium symporters participate in the enterohepatic circulation of bile acids. Two homologous transporters are involved in the reabsorption of bile acids. One of these absorbs bile acids from the intestinal lumen, the bile duct, and the kidney with an apical localization (ileal sodium/bile acid cotransporter). The other is this protein and is expressed in the basolateral membranes of hepatocytes (NTCP).[7]

As a cotransporter, NTCP binds two sodium ions and one (conjugated) bile salt molecule, thereby providing a hepatic influx of bile salts. Other transported molecules include steroid hormones, thyroid hormones and various xenobiotics:[7]

Hepatitis virus entry

NTCP is a cell surface receptor necessary for the entry of hepatitis B and hepatitis D virus.[8] This entry mechanism is inhibited by myrcludex B,[9] cyclosporin A, progesterone, propranolol, bosentan, ezetimibe, as well as NTCP substrates like taurocholate, tauroursodeoxycholate and bromosulfophthalein.[7]

SLC10A1-deficiency

Individuals that lack functional NTCP have been identified.[10] These individuals display highly elevated bile salt levels in plasma, but without a clear phenotype. In areas of the world with a high prevalence of HBV, there are multiple individuals who carry the NTCP p.S267F polymorphism on both alleles; this makes NTCP inactive as a bile acid transporter, but provides protection against HBV infection.[11]

NTCP-deficient mice have also been created. These mice have reduced hepatic bile salt uptake but plasma bile salt levels are less clearly elevated, as the rodent-specific OATP1a/1b transporters provide can partially replace the function of NTCP.[12] Nevertheless, this NTCP-knockout animal model pointed to possible additional (non-HBV) aspects of NTCP-deficiency. NTCP-deficient mice are partially protected against the problems associated with a high-calorie diet, including excessive weight gain[13] and to liver damage in cholestasis.[14] These effects of NTCP deficiency have not yet been replicated in humans.

See also

References
  1. GRCh38: Ensembl release 89: ENSG00000100652 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000021135 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. "Entrez Gene: SLC10A1 solute carrier family 10 (sodium/bile acid cotransporter family), member 1".
  6. Hagenbuch B, Meier PJ (March 1994). "Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter". The Journal of Clinical Investigation. 93 (3): 1326–31. doi:10.1172/JCI117091. PMC 294097. PMID 8132774.
  7. Watashi K, Urban S, Li W, Wakita T (February 2014). "NTCP and beyond: opening the door to unveil hepatitis B virus entry". International Journal of Molecular Sciences. 15 (2): 2892–905. doi:10.3390/ijms15022892. PMC 3958888. PMID 24557582.
  8. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W (November 2012). "Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus". eLife. 1: e00049. doi:10.7554/eLife.00049. PMC 3485615. PMID 23150796.
  9. H. Spreitzer (14 September 2015). "Neue Wirkstoffe – Myrcludex B". Österreichische Apothekerzeitung (in German) (19/2015): 12.
  10. Vaz, FM; Paulusma, CC; Huidekoper, H; de Ru, M; Lim, C; Koster, J; Ho-Mok, K; Bootsma, AH; Groen, AK; Schaap, FG; Oude Elferink, RP; Waterham, HR; Wanders, RJ (January 2015). "Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype". Hepatology. 61 (1): 260–7. doi:10.1002/hep.27240. PMID 24867799.
  11. Peng, L; Zhao, Q; Li, Q; Li, M; Li, C; Xu, T; Jing, X; Zhu, X; Wang, Y; Li, F; Liu, R; Zhong, C; Pan, Q; Zeng, B; Liao, Q; Hu, B; Hu, ZX; Huang, YS; Sham, P; Liu, J; Xu, S; Wang, J; Gao, ZL; Wang, Y (April 2015). "The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B.". Hepatology. 61 (4): 1251–60. doi:10.1002/hep.27608. PMID 25418280.
  12. Slijepcevic, D; Kaufman, C; Wichers, CG; Gilglioni, EH; Lempp, FA; Duijst, S; de Waart, DR; Elferink, RP; Mier, W; Stieger, B; Beuers, U; Urban, S; van de Graaf, SF (July 2015). "Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in Na(+) -taurocholate cotransporting polypeptide knockout mice". Hepatology. 62 (1): 207–19. doi:10.1002/hep.27694. PMC 4657468. PMID 25641256.
  13. Donkers, JM; Kooijman, S; Slijepcevic, D; Kunst, RF; Roscam Abbing, RL; Haazen, L; de Waart, DR; Levels, JH; Schoonjans, K; Rensen, PC; Oude Elferink, RP; van de Graaf, SF (25 June 2019). "NTCP deficiency in mice protects against obesity and hepatosteatosis". JCI Insight. 5 (14). doi:10.1172/jci.insight.127197. PMC 6675549. PMID 31237863.
  14. Slijepcevic, D; Roscam Abbing, RLP; Fuchs, CD; Haazen, LCM; Beuers, U; Trauner, M; Oude Elferink, RPJ; van de Graaf, SFJ (24 March 2018). "Na+ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice". Hepatology. 68 (3): 1057–1069. doi:10.1002/hep.29888. PMC 6175374. PMID 29572910.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.